• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Brooklyn ImmunoTherapeutics Welcomes Erin S. Enright and Heather B. Redman to Its Board of Directors

    1/20/22 7:30:00 AM ET
    $BTX
    Get the next $BTX alert in real time by email

    NEW YORK, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NASDAQ:BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announces the appointment of two new members of the Company's Board of Directors.

    Erin S. Enright has served on multiple Boards of Directors, including within the medical and life sciences arenas, such as Keystone Dental (serving as Audit Committee Chair), Medical Facilities Corporation (serving as Audit and Investment Committee Chair), and Dynatronics Corporation (serving on the Audit, Compensation, Nominating and Governance Committees). She is currently managing partner and co-founder of Prettybrook Partners, LLC, an investment firm specializing in medical technology and healthcare services companies. She holds a J.D. from University of Chicago and a B.A. from Princeton University.

    Heather B. Redman is a well-credentialed board member, serving such organizations as PPL Corporation (serving on the Audit and Finance Committees),Beneficial State Bank (serving on the Audit and Technology Committees), Coldstream Holdings, Inc. (serving on the Compensation and Nomination and Governance Committees), the Washington State University Board of Regents and Foundation (serving on the Investment Committee), and the Institute for Systems Biology. She is currently managing partner of Flying Fish Partners, a Seattle-based venture capital firm investing in artificial intelligence. She holds a J.D. from Stanford University Law School and a B.A. from Reed College.

    "We are at an inflection point in the development of our company and we believe we are both staffing and recruiting advisors to help guide us to the next step in the evolution of Brooklyn ImmunoTherapeutics," commented Brooklyn's Chief Executive Officer and President Howard Federoff, M.D., Ph.D. "Heather's extensive financial and technology background, combined with her deep experience as a key member of several boards of directors, makes her an excellent fit for our Board, and we look forward to continued growth under her guidance and counsel. Meanwhile, Erin has worked extensively with public companies as an investment banker and investor. We look forward to her contribution as Brooklyn continues to traverse the public markets as it develops new compounds to address rare diseases that are not adequately managed."

    "I look forward to working with Brooklyn's management team and my fellow Board members to help the Company maintain its already impressive efficiencies while achieving leadership among companies developing therapeutics for rare diseases," commented Ms. Enright.

    "I believe Brooklyn ImmunoTherapeutics is at a tipping point in its growth as it is now focusing on its development platform. I'm looking forward to collaborating with my fellow Board members as we help to further Brooklyn's progress in the public markets as it addresses significant unmet medical needs," commented Ms. Redman.

    About Brooklyn ImmunoTherapeutics

    Brooklyn is focused on exploring the role that cytokine, gene editing, and cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases.

    Brooklyn's most advanced program is IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B. In a Phase 2A clinical trial in head and neck cancer, IRX-2 demonstrated an overall survival benefit. Additional studies are either underway or planned in other solid tumor cancer indications.

    Brooklyn has multiple next-generation cell and gene-editing therapies in preclinical development for various indications including acute respiratory distress syndrome, solid tumor indications, as well as in vivo gene-editing therapies for rare genetic diseases. For more information about Brooklyn and its clinical programs, please visit www.BrooklynITx.com.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward looking statements are statements that are not historical facts. Words such as "expects," "believes," "will," "may," "anticipates," "intends," "plans," "estimates," "seek," "predict," "project," "potential" or the negatives of these terms or variations of them or similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding our financial position, market opportunities, our clinical and preclinical trials and our ability to obtain regulatory approval for any of our product candidates. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management, and are subject to a number of risks and uncertainties. Factors that could cause actual results to differ materially from current expectations include, without limitation: our dependence on the success of our internal development programs; whether or not our product pipeline candidates successfully complete clinical trials, receive regulatory approval and can be successfully commercialized; our ability to fund, enroll and complete our clinical trials; whether we generate the expected benefits of any acquisitions or joint ventures; our ability to maintain orphan drug exclusivity for IRX-2; undesirable side effects of our current or future product candidates; the impact of the current pandemic of the novel coronavirus (COVID-19) and its impacts on our business, including our ability to enroll persons in our clinical trials; our limited operating history; and the cautionary statements and risk factors described in our Current Report on Form 8-K filed with the Securities and Exchange Commission on May 11, 2021, our Quarterly Report on Form 10-Q for the quarter ended September 30, 2021 and our other filings filed from time to time with the Securities and Exchange Commission. We do not assume any obligation to update any forward-looking statement, except as required by law.

    Investor Relations Contact:

    CORE IR

    516-222-2560

    [email protected]

    Media Contact:

    Jules Abraham

    CORE IR

    917-885-7378

    [email protected]



    Primary Logo

    Get the next $BTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BTX

    DatePrice TargetRatingAnalyst
    12/29/2021$9.00Overweight
    Cantor Fitzgerald
    10/6/2021$20.00Buy
    Maxim Group
    More analyst ratings

    $BTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on Brooklyn with a new price target

      Cantor Fitzgerald initiated coverage of Brooklyn with a rating of Overweight and set a new price target of $9.00

      12/29/21 7:03:49 AM ET
      $BTX
    • Maxim Group initiated coverage on Brooklyn ImmunoTherapeutics with a new price target

      Maxim Group initiated coverage of Brooklyn ImmunoTherapeutics with a rating of Buy and set a new price target of $20.00

      10/6/21 7:53:44 AM ET
      $BTX

    $BTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Brooklyn ImmunoTherapeutics Announces Changes to Executive Management: Matt Angel, Ph.D. Appointed Interim Chief Executive Officer and President, Andrew Jackson Appointed Chief Financial Officer Postpones 2022 Annual Meeting

      SAN DIEGO, May 31, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NASDAQ:BTX) ("Brooklyn" or the "Company"), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and cell therapy can have on the immune system for treating patients with cancer, blood disorders, and monogenic diseases, today announced the appointment of Matt Angel, Ph.D., Co-Founder, Chairman, and CEO of Factor Bioscience Inc., as Interim Chief Executive Officer and President. He will replace Howard J. Federoff, M.D., Ph.D., Chief Executive Officer and President, who departs to focus on building a new venture. The Company also announces the appointment of Andrew Jackson as Chief

      5/31/22 7:30:00 AM ET
      $BTX
    • Amarin Announces Appointment of New Directors and Board Leadership Changes

      Erin Enright and Alfonso "Chito" Zulueta Appointed to Board of Directors New Board Members Bring Skills and Experience Aligned with the Company's Strategy Per Wold-Olsen Named Chairman of the Board David Stack and Joe Zakrzewski to Retire from the Board Actions Reflect Company and Board's Commitment to Ongoing Refreshment and Enhancement DUBLIN, Ireland and BRIDGEWATER, N.J., May 19, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced a series of appointments and leadership changes to its Board of Directors, including: Appointment of Erin Enright and Alfonso "Chito" Zulueta to the Board, effective immediately. Ms. Enright and Mr. Zulueta will sta

      5/19/22 8:23:13 AM ET
      $AMRN
      $BTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Brooklyn ImmunoTherapeutics Welcomes Erin S. Enright and Heather B. Redman to Its Board of Directors

      NEW YORK, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NASDAQ:BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announces the appointment of two new members of the Company's Board of Directors. Erin S. Enright has served on multiple Boards of Directors, including within the medical and life sciences arenas, such as Keystone Dental (serving as Audit Committee Chair), Medical Facilities Corporation (serving as Audit and Investment Committee Chair), and Dynatronics Corporation (serving on the Audit, Compensati

      1/20/22 7:30:00 AM ET
      $BTX

    $BTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Cicala Peter

      3 - Eterna Therapeutics Inc. (0000748592) (Issuer)

      2/16/24 5:30:35 PM ET
      $BTX
    • SEC Form 4 filed by Luther Sanjeev

      4 - Eterna Therapeutics Inc. (0000748592) (Issuer)

      1/3/24 5:02:56 PM ET
      $BTX
    • SEC Form 4 filed by Clarke Dorothy J

      4 - Eterna Therapeutics Inc. (0000748592) (Issuer)

      1/3/24 5:01:31 PM ET
      $BTX

    $BTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Brooklyn ImmunoTherapeutics Inc. (Amendment)

      SC 13G/A - Eterna Therapeutics Inc. (0000748592) (Subject)

      1/31/24 7:05:56 AM ET
      $BTX
    • SEC Form SC 13G/A filed by Brooklyn ImmunoTherapeutics Inc. (Amendment)

      SC 13G/A - Eterna Therapeutics Inc. (0000748592) (Subject)

      1/19/24 10:31:54 AM ET
      $BTX
    • SEC Form SC 13D/A filed by Brooklyn ImmunoTherapeutics Inc. (Amendment)

      SC 13D/A - Eterna Therapeutics Inc. (0000748592) (Subject)

      12/22/23 12:05:20 PM ET
      $BTX

    $BTX
    SEC Filings

    See more
    • SEC Form DEFA14A filed by BlackRock Technology and Private Equity Term Trust

      DEFA14A - BlackRock Technology & Private Equity Term Trust (0001836057) (Filer)

      3/28/25 2:46:10 PM ET
      $BTX
    • SEC Form N-CEN filed by BlackRock Technology and Private Equity Term Trust

      N-CEN - BlackRock Technology & Private Equity Term Trust (0001836057) (Filer)

      3/17/25 9:47:53 AM ET
      $BTX
    • SEC Form DEF 14A filed by BlackRock Technology and Private Equity Term Trust

      DEF 14A - BlackRock Technology & Private Equity Term Trust (0001836057) (Filer)

      3/12/25 4:33:33 PM ET
      $BTX

    $BTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Distribution Dates and Amounts Announced for Certain BlackRock Closed-End Funds

      Certain BlackRock closed-end funds (the "Funds") announced distributions today as detailed below. Municipal Funds: National Funds Ticker Distribution   Declaration- 5/1/2025 Ex-Date- 5/15/2025 Record- 5/15/2025 Payable- 6/2/2025   Ticker Distribution Change From Prior Distribution BlackRock Municipal Income Quality Trust* BYM $0.055500 - BlackRock Long-Term Municipal Advantage Trust* BTA $0.049500 - BlackRock MuniAssets Fund, Inc.* MUA $0.055500 - BlackRock Municipal Income Trust* BFK $0.050000 - BlackRock Investment Quality Municipal Trust, Inc.* BKN $0.057000 - BlackRock Municipal Incom

      5/1/25 7:59:00 PM ET
      $BBN
      $BCAT
      $BCX
      $BDJ
      Finance Companies
      Finance
      Finance/Investors Services
      Trusts Except Educational Religious and Charitable
    • Certain BlackRock Closed-End Funds Announce Estimated Sources of Distributions

      Today, BlackRock Resources & Commodities Strategy Trust (NYSE:BCX), BlackRock Enhanced Equity Dividend Trust (NYSE:BDJ), BlackRock Energy and Resources Trust (NYSE:BGR), BlackRock Enhanced International Dividend Trust (NYSE:BGY), BlackRock Health Sciences Trust (NYSE:BME), BlackRock Health Sciences Term Trust (NYSE:BMEZ), BlackRock Enhanced Global Dividend Trust (NYSE:BOE), BlackRock Utilities, Infrastructure & Power Opportunities Trust (NYSE:BUI), BlackRock Enhanced Large Cap Core Fund, Inc. (NYSE:CII), BlackRock Science and Technology Trust (NYSE:BST), BlackRock Science and Technology Term Trust (NYSE:BSTZ), BlackRock Technology and Private Equity Term Trust (NYSE:BTX), BlackRock Capital

      4/30/25 7:40:00 PM ET
      $BBN
      $BCAT
      $BCX
      $BDJ
      Finance Companies
      Finance
      Finance/Investors Services
      Trusts Except Educational Religious and Charitable
    • BlackRock Announces Shareholder Approval of Strategy Changes to the BlackRock Technology and Private Equity Term Trust (BTX)

      BlackRock Advisors, LLC announced today the results of the Special Shareholder Meeting of the BlackRock Technology and Private Equity Term Trust (NYSE:BTX) (the "Trust"). Shareholders have approved (i) an amendment to the Trust's fundamental investment restriction with respect to industry concentration to allow the Trust to concentrate its investments in companies operating in one or more industries within the technology group of industries and (ii) a change in the Trust's diversification status under the Investment Company Act of 1940 from diversified to non-diversified. About BlackRock BlackRock's purpose is to help more and more people experience financial well-being. As a fiduciary to

      4/17/25 4:30:00 PM ET
      $BTX

    $BTX
    Financials

    Live finance-specific insights

    See more
    • Distribution Dates and Amounts Announced for Certain BlackRock Closed-End Funds

      Certain BlackRock closed-end funds (the "Funds") announced distributions today as detailed below. Municipal Funds: National Funds Ticker Distribution   Declaration- 5/1/2025 Ex-Date- 5/15/2025 Record- 5/15/2025 Payable- 6/2/2025   Ticker Distribution Change From Prior Distribution BlackRock Municipal Income Quality Trust* BYM $0.055500 - BlackRock Long-Term Municipal Advantage Trust* BTA $0.049500 - BlackRock MuniAssets Fund, Inc.* MUA $0.055500 - BlackRock Municipal Income Trust* BFK $0.050000 - BlackRock Investment Quality Municipal Trust, Inc.* BKN $0.057000 - BlackRock Municipal Incom

      5/1/25 7:59:00 PM ET
      $BBN
      $BCAT
      $BCX
      $BDJ
      Finance Companies
      Finance
      Finance/Investors Services
      Trusts Except Educational Religious and Charitable
    • Certain BlackRock Closed-End Funds Announce Estimated Sources of Distributions

      Today, BlackRock Resources & Commodities Strategy Trust (NYSE:BCX), BlackRock Enhanced Equity Dividend Trust (NYSE:BDJ), BlackRock Energy and Resources Trust (NYSE:BGR), BlackRock Enhanced International Dividend Trust (NYSE:BGY), BlackRock Health Sciences Trust (NYSE:BME), BlackRock Health Sciences Term Trust (NYSE:BMEZ), BlackRock Enhanced Global Dividend Trust (NYSE:BOE), BlackRock Utilities, Infrastructure & Power Opportunities Trust (NYSE:BUI), BlackRock Enhanced Large Cap Core Fund, Inc. (NYSE:CII), BlackRock Science and Technology Trust (NYSE:BST), BlackRock Science and Technology Term Trust (NYSE:BSTZ), BlackRock Technology and Private Equity Term Trust (NYSE:BTX), BlackRock Capital

      4/30/25 7:40:00 PM ET
      $BBN
      $BCAT
      $BCX
      $BDJ
      Finance Companies
      Finance
      Finance/Investors Services
      Trusts Except Educational Religious and Charitable
    • Distribution Dates and Amounts Announced for Certain BlackRock Closed-End Funds

      Certain BlackRock closed-end funds (the "Funds") announced distributions today as detailed below. Municipal Funds: National Funds Ticker Distribution   Declaration- 4/1/2025 Ex-Date- 4/15/2025 Record- 4/15/2025 Payable- 5/1/2025   Ticker Distribution Change From Prior Distribution   BlackRock Municipal Income Quality Trust*  BYM $0.055500 - BlackRock Long-Term Municipal Advantage Trust* BTA $0.049500 - BlackRock MuniAssets Fund, Inc.* MUA $0.055500 - BlackRock Municipal Income Trust* BFK $0.050000 - BlackRock Investment Quality Municipal Trust, Inc.* BKN $0.057000 - BlackRock Municip

      4/1/25 6:55:00 PM ET
      $BBN
      $BCAT
      $BCX
      $BDJ
      Finance Companies
      Finance
      Finance/Investors Services
      Trusts Except Educational Religious and Charitable